Berlin Heart Receives First Regulatory Approval in Nor...( BERLIN April 3 /- Berlin Heart Gm...),Health
BERLIN, April 3 /PRNewswire/ -- Berlin Heart GmbH today announced it has received its first marketing approval in North America. The EXCOR(R) Pediatric ventricular assist device received the License with Conditions from Health Canada, the Federal Department responsible for regulatory issues in Canada.
The Berlin Heart EXCOR Pediatric is a mechanical cardiac support system for critically ill pediatric patients suffering from severe heart failure. EXCOR Pediatric has been used as a short-term, mid-term, and long-term support system, supporting failing hearts from days up to several months.
The system is designed to bridge patients awaiting heart transplantation until a donor heart becomes available, but has also been used successfully as a bridge to recovery when a patient's heart was able to recover and work on its own again. Unlike other VADs, EXCOR Pediatric can be used to support children of all age groups, from newborns up to teenagers.
Dr. Johannes Muller, General Manager of Berlin Heart, comments: "The license with conditions represents a milestone reached for children and teenagers suffering from severe heart failure, as the system is now more readily available in Canada. Since patients often require acute emergency support, this is a major step toward improved care for these potentially terminally ill children."
Since the application for Canadian regulatory approval in September 2007, 21 patients were supported in Canada with EXCOR Pediatric under special access approval.
About EXCOR(R) Pediatric
EXCOR Pediatric is a pulsatile, pneumatically driven ventricular assist
device and can be used to support one or both ventricles. EXCOR Pediatric has
been used in more than 500 pediatric patients worldwide ranging from newborns
with 2.2 kg body weight to teenagers. Since the first application of the
ventricular assist device in Canada in July 2002, 39
'/>"/>
| SOURCE Berlin Heart GmbH Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Charterhouse Group Partners with MTS Health Investors and Highlander Partners to Acquire Chamberlin Edmonds & Associates, Inc., a Leading Provider of Eligibility Services to Hospitals
2. Drug for cluster headaches may cause heart problems
3. Use of certain lipid measures not more effective in predicting coronary heart disease
4. Restricting Blood Flow May Help Heart Bypass Patients
5. Urban Smog Tough on Young Adults Hearts
6. Stanford study highlights cost-effective method of lowering heart disease risks
7. Vitamin Es lack of heart benefit linked to dosage
8. Drug That Lowers Resting Heart Rate Being Tested
9. Heart Attack Boosts Diabetes Risk
10. Embryonic Stem Cells Repair Human Heart
11. U of M study: Early treatment can reverse heart damage
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |